Know with confidence who will benefit from chemotherapy and who will not1-4
The National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its updated guidance once again recommending the Oncotype DX Breast Recurrence Score test for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer. Furthermore, NICE expanded the recommendation to now also include patients with micro metastases, indicating that some cancer cells have spread to the lymph nodes.
The recommendation of the Oncotype DX test in this updated guidance is based on its unique ability to predict who will benefit from chemotherapy and who will not. NICE acknowledges that Oncotype DX is:
- the only test to overall reduce the number of patients who receive chemotherapy
- the only test supported by long-term patient outcomes evidence, including the TAILORx study
- and the most cost-effective tool to guide chemotherapy treatment.
The Oncotype DX assay is incorporated in major clinical guidelines
FOR YOUR PATIENTS WITH HR+, HER2–, NODE-NEGATIVE, EARLY-STAGE, INVASIVE BREAST CANCER
The Oncotype DX Breast Recurrence Score test provides clarity for adjuvant treatment decisions